Valuation: Immunovia AB

Market Cap 96.06M 9.84M 8.52M 8.04M 7.3M 13.69M 943M 13.79M 37.01M 478M 36.94M 36.13M 1.52B P/E 2026 *
-1.43x
P/E 2027 * -3.57x
Enterprise Value 61.06M 6.25M 5.42M 5.11M 4.64M 8.7M 599M 8.76M 23.53M 304M 23.48M 22.96M 966M EV / Sales 2026 *
19.1x
EV / Sales 2027 * 3.82x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+24,682.61%
Current month+22,996.96%
1 month+18,809.95%
3 months+17,400.00%
6 months+19,603.70%
Current year+13,658.62%
1 month 0.13
Extreme 0.1288
0.32
Current year 0.13
Extreme 0.1288
0.32
1 year 0.13
Extreme 0.1288
0.7
3 years 0.13
Extreme 0.1288
2.78
5 years 0.13
Extreme 0.1288
131.5
10 years 0.13
Extreme 0.1288
292
Manager TitleAgeSince
Chief Executive Officer 53 2023-04-28
Chief Tech/Sci/R&D Officer 55 2024-04-28
Chief Tech/Sci/R&D Officer 54 2024-01-30
Director TitleAgeSince
Director/Board Member 72 2016-12-08
Chairman 69 2023-05-25
Director/Board Member 51 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+24,682.61% - - 9.91M
-2.15%-2.48%+15.13%-33.42% 16.73B
+1.03%+6.31%-34.38%+45.06% 1.75B
+0.41%-1.83%-28.49%+22.12% 893M
-4.97%-15.84%-61.07%-85.26% 808M
+0.08%-0.03%+61.02%-2.51% 778M
+0.19%-4.99%-38.74%-49.84% 637M
+1.76%-8.00%-42.32%-51.29% 560M
-0.90%-12.45%-43.86%-39.58% 450M
-0.25%-0.62%-8.52%-4.73% 397M
Average -3.39%-5.46%-20.14%-22.16% 2.56B
Weighted average by Cap. -1.39%-2.59%+4.09%-26.58%

Financials

2026 *2027 *
Net sales 3.2M 328K 284K 268K 243K 456K 31.41M 459K 1.23M 15.93M 1.23M 1.2M 50.65M 17.3M 1.77M 1.53M 1.45M 1.31M 2.47M 170M 2.48M 6.67M 86.13M 6.65M 6.51M 274M
Net income -87M -8.91M -7.72M -7.28M -6.61M -12.4M -854M -12.49M -33.52M -433M -33.46M -32.72M -1.38B -76M -7.78M -6.74M -6.36M -5.77M -10.83M -746M -10.91M -29.29M -378M -29.23M -28.58M -1.2B
Net Debt -35M -3.58M -3.11M -2.93M -2.66M -4.99M -343M -5.02M -13.49M -174M -13.46M -13.16M -554M -30M -3.07M -2.66M -2.51M -2.28M -4.27M -294M -4.31M -11.56M -149M -11.54M -11.28M -475M
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume
26-09-07 SEK 0.1406 +9.16% 46,208

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!